Global Parkinson’s Disease Drugs Market 2018-2023: Recent Drug Approvals are Driving Growth - ResearchAndMarkets.com

September 19, 2018

DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Global Parkinson’s Disease Drugs Market - Segmented by Mechanism of Action and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.

The Parkinson’s disease drugs market is expected to witness a CAGR of 6.2% during the forecast period, 2018-2023. The global Parkinson’s disease drug market has witnessed a remarkable growth in the recent years, due to a large patient pool and increased diagnosis rates.

Recent Drug Approvals

Researchers are working to develop new and improved therapies for people with Parkinson’s disease (PD). There have been many drugs that have been approved to treat Parkinson disease. In January 2015, the US FDA approved an extended release formulation of levodopa/carbidopa.Recently in January 2018, Adamas Pharmaceuticals Inc. has launched Gocovri (amantadine extended-release capsules) for the treatment of dyskinesia in people with Parkinson’s, who are taking levodopa. This is the first drug indicated specifically for dyskinesia, which is developed with the long-term usage of levodopa.These newly-approved drugs, with different formulations, are addressing different unmet needs and are expected to drive the Parkinson disease drug market.

The other factors, which are also driving the market, include increasing demand due to the higher prevalence of the disease, new entrants expected to balance generic intrusion, and increasing use of the MAO-B inhibitor.

Key HighlightsGeneric Competition to Key Therapies - Restraining the MarketEurope Holds the Largest Share of the Market

Major Market Developments

Pfizer, the world’s third-largest drug maker, announced that it is ending research to discover new medications for Alzheimer’s and Parkinson’s diseases, due to the high cost involved.Adamas Pharmaceuticals Inc. launched Gocovri (amantadine extended-release capsules) for the treatment of dyskinesia.Companies FeaturedMerck & Co. Inc.Impax Laboratories Inc.Abbvie Inc.Mylan N.V.Boehringer IngelheimGlaxoSmithKline plcSomerset Pharmaceuticals Inc.Teva PharmaceuticalsPfizerNovartis AGJohnson & Johnson (Janssen)Allergan plc

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. The Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/629qdk/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005374/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/19/2018 07:46 AM/DISC: 09/19/2018 07:46 AM


Update hourly